← Back to Search

Prostaglandin Analog

Travoprost Cream for Glaucoma

Phase 2

Recruiting

Research Sponsored by Glaukos Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of OAG (including pigmentary and pseudoexfoliative) or OHT in both eyes

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 29

Awards & highlights

Study Summary

This trial studies a new eye cream to help lower eye pressure in people with glaucoma or high eye pressure.

Who is the study for?

This trial is for adults over 18 with open-angle glaucoma or ocular hypertension in both eyes, who can legally consent and have a visual acuity of about 20/80. It's not for those allergic to travoprost or timolol, with severe asthma/COPD, certain heart conditions, cerebrovascular issues, other types of glaucoma, advanced vision loss or specific eye surgeries.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of Travoprost Ophthalmic Topical Cream at three different doses in reducing high intraocular pressure compared to Timolol maleate solution and Travoprost ophthalmic solution.See study design

What are the potential side effects?

Potential side effects may include eye redness, discomfort or irritation; changes in eyelash growth; darkening of the iris; dry mouth; fatigue; headache; and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with open-angle glaucoma or high eye pressure in both eyes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 29

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 29

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 29 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

change from baseline in mean diurnal IOP in the study eye

Trial Design

5Treatment groups

Experimental Treatment

Active Control

Group I: Travoprost Ophthalmic Topical Cream mid-doseExperimental Treatment1 Intervention

Travoprost Ophthalmic Topical Cream mid-dose administered once-daily in the evening for 28 days

Group II: Travoprost Ophthalmic Topical Cream low-doseExperimental Treatment1 Intervention

Travoprost Ophthalmic Topical Cream low-dose administered once-daily in the evening for 28 days

Group III: Travoprost Ophthalmic Topical Cream high-doseExperimental Treatment1 Intervention

Travoprost Ophthalmic Topical Cream high-dose administered once-daily in the evening for 28 days

Group IV: Timolol maleate ophthalmic solution, 0.5%Active Control1 Intervention

Timolol maleate ophthalmic solution, 0.5% administered twice daily, morning and evening, for 28 days

Group V: Travoprost ophthalmic solution, 0.004%Active Control1 Intervention

Travoprost ophthalmic solution, 0.004% administered once daily in the evening for 28 days

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Glaukos CorporationLead Sponsor

65 Previous Clinical Trials

8,790 Total Patients Enrolled

Study DirectorStudy DirectorGlaukos Corporation

1,211 Previous Clinical Trials

489,022 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there presently opportunities to join this trial?

"Information posted on clinicaltrials.gov affirms that this medical research is not currently in the process of recruitment. It was initially published on November 1st 2023 and last updated a few weeks later, yet there are still 920 studies actively seeking participants."

Answered by AI

To what extent is Travoprost Ophthalmic Topical Cream low-dose perilous to individuals?

"The safety of Travoprost Ophthalmic Topical Cream low-dose was judged a 2, as there is only some data to support its safety and no prior research affirming efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

2023. "Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06152861.

All > Glaucoma Long Beach > Glaucoma